Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: II

34 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Chung, Alice	IIT2015-06-CHUNG-SNBO	Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396)
Faries, Mark	MRNA-4157-P201	MRNA-4157-P201: A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (IRB#57650)
Figlin, Robert	PT2977-201	PT2977-201: A Phase 2 Trial of PT2977 In Combination With Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (IRB#54237)
Forscher, Charles	KCP-330-020	KCP-330-020: A Phase 2-3, Multicenter, Randomized, Doubleblind Study Of Selinexor (KPT-330) Versus Placebo In Patients With Advanced Unresectable Dedifferentiated Liposarcoma DDLS) (IRB#53507)
Freedland, Stephen	IIT2018-06-FREEDLAND-AS3	IIT2018-06-FREEDLAND-AS3 (CAPS3): Carbohydrate and Prostate Study 3: Carbohydrate restricted diet intervention for men on prostate cancer active surveillance (IRB#53710)
Freedland, Stephen	IIT2018-23-FREEDLAND-POWR	IIT2018-23-Freedland-POWR: WALNUTS for POWER: Polyphenols, Omega-3 fatty acids, Weight loss, and EneRgy (IRB#55792)
Goodman, Marc	IIT2016-14-GOODMAN-NWUHCC	Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer (IRB#47043)
Hamid, Omid	CPDR001J2201	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (IRB#53431)
Hamid, Omid	GO40558	GO40558: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma (IRB#54796)
Hamid, Omid	IMCGP100-202	IMCgp100-202:A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma (IRB#48311)
Hamid, Omid	S19-00008	S19-00008: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma (IRB #390)
Hamid, Omid	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Hendifar, Andrew	MK-3475-158	MK-3475-158-00: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (IRB#43687)
Hendifar, Andrew	MK-7339-002	MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241)
Hendifar, Andrew	MK-7902-005	MK-7902-005: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (IRB#0057697)
Hussain, Shehnaz	IIT2017-08-HUSSAIN-STATLV	IIT2017-08-HUSSAIN-STATLV : Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence (IRB#48985)
Jordan, Stanley	CLAZACOVID19	A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 monoclonal) compared to placebo for the treatment of COVID-19 infection
Lo, Simon	NANOPAC-2016-05	NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989)
Majlessipour, Fataneh	AALL15P1	AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement. (IRB#51568)
Majlessipour, Fataneh	APEC1621B	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (IRB#57477)
Majlessipour, Fataneh	APEC1621MASTER-APEC1621SC	APEC1621MASTER-APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master and Screening Protocol (IRB#57413)
McArthur, Heather	IIT2018-01-MCARTHUR-IPI	IIT2018-01-McArthur-IPI: A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (IRB#52157)
McArthur, Heather	IIT2018-04-MCARTHUR-NEOHP	IIT2018-04-MCARTHUR-NEOHP: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (IRB#53566)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Alain	P1719-SUR-Z11	P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155)
Natale, Ronald	D6186C00001	D6186C00001:A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) (IRB#97)
Noureddin, Mazen	GS-US-454-5533	A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH)
Shiao, Stephen	IIT2017-07-HO-PEMBRORT	IIT2017-07-HO-PEMBRORT: Pilot Study of the Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients with Operable Breast Cancer (IRB#49440)
Tapson, Victor	20-0006	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Wentzel, Kristopher	8951-CL-0103	A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384)
Yang, Ju Dong	IIT2020-01-YANG-G1001	IIT2020-01-YANG-G1001:Case-Control Study of the Glycotest HCC Panel vs AFP for the Detection of Early-Stage Hepatocellular Carcinoma (IRB#399)
Yu, John	ATI001-204	ATI001-204: A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo®) in Subjects with Recurrent or Progressive Glioblastoma (IRB#12)
Zumsteg, Zachary	NRG-HN004	NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (IRB#46)
Zumsteg, Zachary	NRG-HN005	NRG-HN005: A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER (IRB#189)